title: [Exacerbation of hepatitis B and the expression of M proteinemia during the treatment of malignant lymphoma: a case study].
authors.forename: J
authors.initials: J
authors.lastname: Akiyama
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: N
authors.initials: N
authors.lastname: Masaki
authors.forename: K
authors.initials: K
authors.lastname: Fukushima
authors.forename: M
authors.initials: M
authors.lastname: Matsukawa
authors.forename: S
authors.initials: S
authors.lastname: Yamato
authors.forename: R
authors.initials: R
authors.lastname: Shoda
authors.forename: R
authors.initials: R
authors.lastname: Muraoka
authors.lastname: Matsueda
authors.forename: E
authors.initials: E
authors.lastname: Shimojo
authors.forename: N
authors.initials: N
authors.lastname: Umeda
authors.forename: A
authors.initials: A
authors.lastname: Togawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002353:Carrier State; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D010265:Paraproteinemias / Q000150:complications*; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014775:Virus Activation
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone